The thiamine prodrug benfotiamine (S-benzoylthiamine-O-monophosphate) has been shown to prevent the formation of advanced glycation endproducts (AGEs), thus decreasing hyperglycaemia-induced damage and neuropathic sensory symptoms. However, recent studies have yielded contradictory results. Other studies emphasize the need for further research on the potential of benfotiamine in the treatment of vascular and diabetes complications. Currently, benfotiamine is considered to be a pathogenetic treatment in counteracting oxidative stress and hyperglycaemia-induced metabolic changes that lead to neuropathy.

Stirban, A., Tesfaye, S., Gurieva, I., Czupryniak, L., Mankovsky, B., Spallone, V., et al. (2014). Benfotiamine: Commentary and update on recent studies. DIABETES, STOFFWECHSEL UND HERZ, 23(4), 203-206.

Benfotiamine: Commentary and update on recent studies

SPALLONE, VINCENZA;
2014-08-20

Abstract

The thiamine prodrug benfotiamine (S-benzoylthiamine-O-monophosphate) has been shown to prevent the formation of advanced glycation endproducts (AGEs), thus decreasing hyperglycaemia-induced damage and neuropathic sensory symptoms. However, recent studies have yielded contradictory results. Other studies emphasize the need for further research on the potential of benfotiamine in the treatment of vascular and diabetes complications. Currently, benfotiamine is considered to be a pathogenetic treatment in counteracting oxidative stress and hyperglycaemia-induced metabolic changes that lead to neuropathy.
20-ago-2014
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/13 - ENDOCRINOLOGIA
English
Senza Impact Factor ISI
Benfotiamine; Diabetes; Hyperglycaemia; Neuropathy
Stirban, A., Tesfaye, S., Gurieva, I., Czupryniak, L., Mankovsky, B., Spallone, V., et al. (2014). Benfotiamine: Commentary and update on recent studies. DIABETES, STOFFWECHSEL UND HERZ, 23(4), 203-206.
Stirban, A; Tesfaye, S; Gurieva, I; Czupryniak, L; Mankovsky, B; Spallone, V; Veresiu, I; Schnell, O; Ziegler, D; Kempler, P
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
StirbanA-SpalloneV.Diabetes, Stoffwechsel und Herz 2014.pdf

solo utenti autorizzati

Descrizione: Articolo preprint
Licenza: Copyright dell'editore
Dimensione 405.99 kB
Formato Adobe PDF
405.99 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/95200
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact